Seelos Therapeutics, Inc.
SEELQ
$0.0005
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 376.00K | 579.00K | 653.00K | 406.00K | 336.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 376.00K | 579.00K | 653.00K | 406.00K | 336.00K |
| Cost of Revenue | 755.00K | 3.53M | 30.12M | -- | 8.24M |
| Gross Profit | -379.00K | -2.95M | -29.46M | 406.00K | -7.91M |
| SG&A Expenses | 2.55M | 3.11M | 2.75M | 2.99M | 2.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.52M | 6.63M | 8.66M | 13.01M | 11.29M |
| Operating Income | -3.14M | -6.06M | -8.01M | -12.60M | -10.95M |
| Income Before Tax | 1.71M | -2.66M | -5.45M | 10.50M | -29.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.71M | -2.66M | -5.45M | 10.50M | -29.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.71M | -2.66M | -5.45M | 10.50M | -29.50M |
| EBIT | -3.14M | -6.06M | -8.01M | -12.60M | -10.95M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 10.92 | -26.21 | -100.67 | 297.88 | -858.54 |
| Normalized Basic EPS | 1.24 | -5.95 | -54.84 | 264.74 | -425.20 |
| EPS Diluted | 1.98 | -26.21 | -100.67 | -444.27 | -858.56 |
| Normalized Diluted EPS | 1.24 | -5.95 | -54.84 | 241.85 | -425.20 |
| Average Basic Shares Outstanding | 156.70K | 101.60K | 54.20K | 35.20K | 34.40K |
| Average Diluted Shares Outstanding | 157.20K | 101.60K | 54.20K | 38.60K | 34.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |